Renal cell carcinoma · line 1 · Belzutifan monotherapy (VHL-disease tumors / mRCC 2L+)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-BELZUTIFAN-MONO`

ID	`IND-RCC-VHL-DISEASE-BELZUTIFAN`
Type	Indication
Status	reviewed 2026-04-26
Diseases	`DIS-RCC`
Sources	`SRC-ESMO-RCC-2024` `SRC-NCCN-KIDNEY-2025`

Notes

Hereditary VHL-syndrome indication. Distinct from sporadic mRCC use. Patient typically has multifocal RCC + CNS hemangioblastomas + pancreatic NETs concurrently — belzutifan addresses all three HIF-2α-driven manifestations. Lifelong therapy expected; monitoring CBC + SpO2 on each cycle. Not used in sporadic ccRCC unless prior IO/VEGF-TKI failure (see IND-RCC-METASTATIC-2L-BELZUTIFAN).

Used By

Algorithms

ALGO-RCC-METASTATIC-2L - ALGO-RCC-METASTATIC-2L
ALGO-VHL-CARRIER-SURVEILLANCE-VHL-ALLIANCE - ALGO-VHL-CARRIER-SURVEILLANCE-VHL-ALLIANCE

Indication

IND-RCC-METASTATIC-2L-BELZUTIFAN - IND-RCC-METASTATIC-2L-BELZUTIFAN